Australian researchers nearly double cure rates for the most common breast cancer

Story: 2025 C.E.  |  Last updated: January 27, 2025

A team of Australian cancer researchers has achieved what many oncologists consider a remarkable leap forward: combining immunotherapy with standard chemotherapy to nearly double cure rates for hormone receptor-positive breast cancer, the most common form of the disease worldwide. The results are already reshaping how clinicians think about treating early-stage breast cancer before surgery.

At a glance

• Breast cancer immunotherapy: Australian researchers tested a combination of immunotherapy and chemotherapy in patients with hormone receptor-positive (HR+) breast cancer — the subtype that accounts for roughly 70% of all breast cancer diagnoses globally.
• Cure rate improvement: The combination treatment nearly doubled the rate of patients achieving a pathological complete response — meaning no detectable cancer remained in the breast or lymph nodes at the time of surgery, a strong predictor of long-term cure.
• Clinical significance: Pathological complete response rates in HR+ breast cancer have historically been low, often below 20%, making this improvement a potentially major step for a cancer type that has lagged behind other subtypes in responding to immunotherapy.

Why this matters for the most common breast cancer

Breast cancer is not one disease. It comes in several subtypes, and the treatments that work dramatically for one can barely move the needle for another.

HR+ breast cancer — driven by the hormones estrogen and progesterone — is the most frequently diagnosed subtype, affecting millions of people each year. It tends to grow more slowly than other subtypes, but it has also been stubbornly resistant to immunotherapy, which has shown spectacular results in cancers like triple-negative breast cancer and melanoma.

That resistance has frustrated researchers for years. HR+ tumors are often described as “immunologically cold” — they don’t attract the immune system’s attention the way other cancers do. The Australian team’s finding suggests that pairing immunotherapy with chemotherapy may help “warm up” these tumors, making them visible to the immune system in a way that treatment alone could not.

Research into breast cancer treatment has advanced considerably in recent decades, but improving outcomes specifically for HR+ patients before surgery — known as neoadjuvant treatment — has remained a persistent challenge. A near-doubling of complete response rates in this context is a result that cancer centers around the world will be watching closely.

Immunotherapy meets its most resistant target

Immunotherapy works by releasing the brakes on the immune system, allowing it to recognize and attack cancer cells. Checkpoint inhibitors — the most widely used class of immunotherapy drugs — block proteins that cancer cells use to hide from immune surveillance.

The challenge with HR+ tumors is that they tend to suppress immune activity in the area around them. Adding chemotherapy to the mix may disrupt that suppression, essentially clearing a path for the immune system to engage.

This approach has been validated in other breast cancer subtypes. The KEYNOTE-522 trial, published in the New England Journal of Medicine, demonstrated that adding the checkpoint inhibitor pembrolizumab to chemotherapy significantly improved outcomes in triple-negative breast cancer. The Australian work extends that logic — carefully and with important caveats — into the HR+ space, where the biology is different and the hurdles are higher.

Australia has built a strong reputation in oncology research. Peter MacCallum Cancer Centre in Melbourne, one of the Southern Hemisphere’s leading cancer research institutions, has contributed to several landmark trials in recent years, part of a broader tradition of Australian contributions to global cancer science. Specific institutional details for this study will be confirmed as the full peer-reviewed publication becomes available.

What a “cure” looks like in this context

When researchers talk about “nearly doubling cure rates,” they are typically referring to pathological complete response — the absence of any residual invasive cancer in the breast tissue and lymph nodes after neoadjuvant (pre-surgery) treatment. It is the closest proxy oncologists have for long-term cure in this setting, and it matters enormously for what happens next.

Patients who achieve a pathological complete response have significantly better long-term survival outcomes. For HR+ breast cancer, where those rates have historically been modest, even a moderate improvement can translate into thousands of additional survivors each year worldwide.

The global burden of HR+ breast cancer is substantial. The World Health Organization estimates that breast cancer is now the most commonly diagnosed cancer globally, with over 2.3 million new cases recorded annually. The majority of those are HR+ cases, meaning any treatment advance in this subtype has an outsized impact on the total number of people who can be helped.

Honest about the limits

Immunotherapy is not without cost. Checkpoint inhibitors can cause serious immune-related side effects, from inflammation of the lungs and liver to hormonal disruption. For HR+ breast cancer patients — many of whom have excellent long-term prognoses even with standard treatment — the risk-benefit calculation is not automatic, and clinicians will need robust long-term data before this combination becomes routine care.

Questions remain about which patients within the HR+ category benefit most, what the optimal dosing and sequencing looks like, and whether the improvement in pathological complete response translates into improved overall survival over decades. These are the questions that will drive the next phase of clinical research — and why this finding, while genuinely exciting, is best understood as a strong step forward rather than a final destination.

Still, for a cancer type that has waited the longest for immunotherapy to deliver on its promise, a near-doubling of response rates is the kind of result that changes the direction of research. Breast Cancer Trials Australia, one of the key networks through which Australian breast cancer research reaches patients, has helped establish the country as a meaningful contributor to the global effort to make this disease survivable for everyone it touches.

For the millions of people diagnosed with HR+ breast cancer each year, that progress is personal. And for those who study falling cancer mortality rates globally, results like these are part of why the trend lines are moving in the right direction.

The work also connects to a broader story about what sustained investment in cancer research — including in countries outside the traditional U.S.-Europe axis — can produce. Just as communities around the world are finding new ways to protect what matters most, researchers in Australia are demonstrating that the next breakthrough in cancer medicine can come from anywhere.

Read more

For more on this story, see: New Atlas

For more from Good News for Humankind, see:

• U.K. cancer death rates are down to their lowest level on record
• Ghana establishes a new marine protected area at Cape Three Points
• The Good News for Humankind archive on health

About this article

• 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
• 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
• 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
• ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.